ArticleFrontiers in medicine2026
Case Report: Paralytic ileus as an early manifestation of evolving neuroleptic malignant syndrome in a patient receiving anti-psychotics.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroleptic malignant syndrome (NMS) is an uncommon, but potentially life- threatening complication of antipsychotic therapy, primarily resulting from central dopaminergic blockade. NMS is a clinical diagnosis and occurs rarely in patients receiving atypical antipsychotics agents. Gastrointestinal manifestations, including severe hypomotility and paralytic ileus, are recognized adverse effects of antipsychotic medications. However, paralytic ileus preceding the characteristic neuromuscular and autonomic features of NMS is exceptionally rare and underrecognized as an early manifestation of the syndrome. We report the case of a 49-year-old man who presented with progressive abdominal distension secondary to intestinal pseudo-obstruction as an early manifestation of NMS. This atypical and underreported presentation highlights the importance of maintaining a high index of suspicion for NMS in patients receiving antipsychotic therapy who develop unexplained gastrointestinal dysmotility. Prompt recognition, immediate discontinuation of the offending antipsychotic agent, and early initiation of treatment with dantrolene and bromocriptine resulted in a favorable clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.